January 29, 2021

January 29, 2021

CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

This was a gutsy trial, a first of its kind head-to-head comparison between two Bruton Tyrosine Kinase (BTK) inhibitors, acalabrutinib and ibrutinib for bragging rights as to who was the best in class for treating chronic lymphocytic leukemia patients.

January 29, 2021

iwCLL 2019: Dr. Nicole Lamanna on Biomarker Testing for Chronic Lymphocytic Leukemia (CLL)

As the science of chronic lymphocytic leukemia has advanced, we have learned much more detailed information about its biology and the specific chromosomes, genes, and proteins that contribute to the disease. Checking for specific abnormalities in chromosomes and genetic variants can help doctors evaluate a patient’s prognosis and predict

January 29, 2021

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

January 29, 2021

CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

iwCLL 2019: Dr. Nicole Lamanna on Biomarker Testing for Chronic Lymphocytic Leukemia (CLL)

ASH 2020: Dr. William Wierda on minimal residual disease (MRD)-guided discontinuation of ibrutinib + venetoclax in chronic lymphocytic leukemia (CLL)

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT